Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Illumina, Inc. (NASDAQ:ILMN)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Illumina, Inc. (NASDAQ:ILMN). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Illumina stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

Illumina Stock Down 0.9%

Shares of NASDAQ:ILMN opened at $212.93 on Thursday. The stock has a market cap of $32.20 billion, a price-to-earnings ratio of 40.94, a PEG ratio of 2.92 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The business’s 50 day moving average is $249.39 and its 200 day moving average is $179.08.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the firm posted $1.34 EPS. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, sell-side analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Illumina News Summary

These are some of the ILMN news items that stood out recently:

• Positive Sentiment: Illumina reported third-quarter 2026 revenue of $1.129 billion and net income of $220 million, and raised its full-year revenue outlook to $4.64 billion–$4.66 billion. The company cited a strong contribution from clinical sequencing consumables, reinforcing demand in a key growth area. Article: How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company introduced an ultrasensitive duplex sequencing workflow for molecular residual disease research, extending its circulating tumor DNA offerings in oncology. It was also selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments may support future clinical sequencing adoption. Article: Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Positive Sentiment: Daiwa Securities raised its price target on Illumina to $228 from $196, signaling improved analyst expectations. Article: Daiwa Securities Adjusts Price Target on Illumina to $228 From $196

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 50,000 shares of Illumina stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $227.17, for a total value of $11,358,500.00. Following the sale, the director owned 488,917 shares of the company’s stock, valued at approximately $111,067,274.89. The trade was a 9.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 1,601,541 shares of company stock valued at $354,755,291 over the last 90 days. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Baker Tilly Wealth Management LLC raised its stake in shares of Illumina by 3.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock worth $355,000 after purchasing an additional 42 shares during the period. Ashton Thomas Securities LLC grew its position in Illumina by 3.3% during the third quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock valued at $369,000 after buying an additional 43 shares during the period. Elevation Wealth Partners LLC grew its position in Illumina by 19.7% during the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock valued at $80,000 after buying an additional 48 shares during the period. Evergreen Capital Management LLC grew its position in Illumina by 0.5% during the third quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock valued at $2,593,000 after buying an additional 50 shares during the period. Finally, Pinnacle Associates Ltd. increased its holdings in Illumina by 2.2% during the third quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock worth $686,000 after buying an additional 54 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ILMN. Royal Bank Of Canada upped their target price on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Argus raised their price target on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Piper Sandler boosted their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Leerink Partners upped their price objective on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $244.24.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.